Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) FCF Margin (2016 - 2025)

Historic FCF Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 320.14%.

  • Spero Therapeutics' FCF Margin rose 2253800.0% to 320.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 68.25%, marking a year-over-year decrease of 517800.0%. This contributed to the annual value of 48.87% for FY2024, which is 170700.0% down from last year.
  • Per Spero Therapeutics' latest filing, its FCF Margin stood at 320.14% for Q3 2025, which was up 2253800.0% from 124.7% recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' FCF Margin registered a high of 343.97% during Q4 2022, and its lowest value of 1364.09% during Q1 2022.
  • Moreover, its 5-year median value for FCF Margin was 155.55% (2024), whereas its average is 275.45%.
  • Within the past 5 years, the most significant YoY rise in Spero Therapeutics' FCF Margin was 13392300bps (2022), while the steepest drop was -11520500bps (2022).
  • Over the past 5 years, Spero Therapeutics' FCF Margin (Quarter) stood at 995.26% in 2021, then surged by 135bps to 343.97% in 2022, then tumbled by -107bps to 23.79% in 2023, then tumbled by -554bps to 155.55% in 2024, then surged by 306bps to 320.14% in 2025.
  • Its FCF Margin was 320.14% in Q3 2025, compared to 124.7% in Q2 2025 and 68.13% in Q1 2025.